Potential Role and Expression Level of Urinary CXCL8 in Different Stages of Incipient Diabetic Nephropathy with Undiminished Creatinine Clearance: A Pilot Study

Background Diabetic nephropathy (DN) is one of the most devastating microvascular complications of diabetes, with a high prevalence and poor prognosis. Early intervention is crucial to improve the outcomes of DN. CXCL8 is related to podocyte damage in incipient DN; however, the role and expression level of CXCL8 have never been elucidated, especially in those with undiminished creatinine clearance. Methods Consecutive inpatients with type 2 diabetes were included in this study. Patients were assigned into four groups based on the Mogensen stage, reflecting pathological features through clinical manifestations: non-DN group, hyperfiltration group, microalbuminuria group and overt DN group. Clinical and laboratory data were retrospectively collected and analyzed. Urinary CXCL8 (uCXCL8) was measured using an enzyme-linked immunosorbent assay (ELISA) method and adjusted for urinary creatinine (Cr) from the same urine sample. Results In total, 88 eligible consecutive inpatients with type 2 diabetes were included in this study. uCXCL8 was differentially expressed in different stages of incipient DN; it decreased in the hyperfiltration phase of incipient DN (1.40±1.01 pg/μmol Cr) and was highly expressed in patients in the microalbuminuria stage (5.01±4.01 pg/μmol Cr). uCXCL8 was positively correlated with age, diabetes course, cystatin C and urinary albuminuria-to-creatinine ratio, but negatively correlated with estimated glomerular filtration rate (P<0.05). uCXCL8 was a risk factor for classic DN after adjusting for age, diabetes course and cystatin C (OR=1.17, 95% CI 0.98–1.4, P=0.045). Conclusion CXCL8 played an important role in the progression of incipient DN. The unique expression profile of uCXCL8 may provide a reference for understanding the prognosis and mechanisms of incipient DN progression. uCXCL8 was an independent risk factor for the development of classic DN.

[1]  Ş. Keşkek,et al.  Direct medical cost of nephropathy in patients with type 2 diabetes , 2021, International Urology and Nephrology.

[2]  G. Zuccotti,et al.  The IL-8-CXCR1/2 axis contributes to diabetic kidney disease. , 2021, Metabolism: clinical and experimental.

[3]  S. Wen,et al.  Chemokines in Prediabetes and Type 2 Diabetes: A Meta-Analysis , 2021, Frontiers in Immunology.

[4]  Tetsuhiro Tanaka,et al.  Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan , 2020, BMJ Open Diabetes Research & Care.

[5]  Fang Li,et al.  The Antagonist of CXCR1 and CXCR2 Protects db/db mice from Metabolic Diseases through Modulating Inflammation. , 2019, American journal of physiology. Endocrinology and metabolism.

[6]  P. Matusz,et al.  Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients. , 2019, Journal of diabetes and its complications.

[7]  M. Chattopadhyay,et al.  Early Urinary Markers for Diabetic and Other Kidney Diseases. , 2018, Current drug targets.

[8]  Shu-Yan Liu,et al.  Clinical significance of serum interleukin‐8 and soluble tumor necrosis factor‐like weak inducer of apoptosis levels in patients with diabetic nephropathy , 2018, Journal of diabetes investigation.

[9]  Wei Duan,et al.  Performance of urinary neutrophil gelatinase-associated lipocalin, clusterin, and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria: a consecutive cohort study , 2017, BMC Nephrology.

[10]  R. MacIsaac,et al.  The impact of hyperfiltration on the diabetic kidney. , 2015, Diabetes & metabolism.

[11]  J. Bouchard,et al.  Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: a prospective study. , 2013, Diabetes research and clinical practice.

[12]  M. Muraguchi,et al.  Increased urinary levels of CXCL5, CXCL8 and CXCL9 in patients with Type 2 diabetic nephropathy. , 2009, Journal of diabetes and its complications.

[13]  P. Bacchetti,et al.  Sample size calculations in clinical research. , 2002, Anesthesiology.

[14]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[15]  C. Mogensen,et al.  The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy , 1983, Diabetes.

[16]  L. Gnudi,et al.  Diabetic Nephropathy: An Overview. , 2020, Methods in molecular biology.

[17]  No Authors Standards of Medical Care in Diabetes — 2021 , 2022, KIDNEYS.